Lv3
350 积分 2021-04-30 加入
Prevention and management of amivantamab-induced dermatologic toxicities: a European expert consensus and practical algorithm
1个月前
已完结
A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) – design and rationale
3个月前
已完结
Current Clinical Features of Diabetic Ketoacidosis in Adults: A German Multicenter Study 2022–2023
7个月前
已关闭
Current Clinical Features of Diabetic Ketoacidosis in Adults: A German Multicenter Study 2022–2023
7个月前
已关闭
HSR25-156: Myelosuppression and Healthcare Resource Utilization in Community Oncology Patients With Limited-Stage Small Cell Lung Cancer (LS-SCLC) Receiving First-Line Therapy With or Without Trilaciclib
7个月前
已关闭
A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancer
8个月前
已完结
PEMBROLIZUMAB VS PLACEBO PLUS PACLITAXEL ± BEVACIZUMAB FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: RESULTS FROM THE PHASE 3 ENGOT-OV65/KEYNOTE-B96 STUDY
8个月前
已关闭
Osimertinib
8个月前
已关闭
Therapeutic Monoclonal Antibodies: Future Prospectives
9个月前
已关闭
Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer
9个月前
已关闭
皖公网安备34019202002308
